Author: Ray, Ranjit; Meyer, Keith; Banerjee, Arup; Basu, Arnab; Coates, Stephen; Abrignani, Sergio; Houghton, Michael; Frey, Sharon E.; Belshe, Robert B.
Title: CHARACTERIZATION OF ANTIBODIES INDUCED BY VACCINATION WITH HEPATITIS C VIRUS ENVELOPE GLYCOPROTEINS Cord-id: 3fvzt1h9 Document date: 2010_9_15
ID: 3fvzt1h9
Snippet: Hepatitis C virus (HCV) envelope glycoproteins, E1 and E2, were used with MF59 adjuvant as a candidate vaccine for a phase I safety and immunogenicity trial. Ten of the 41 vaccinee sera tested displayed a VSV/HCV surrogate pseudotype neutralization titer of ≥1/20, 15 of the 36 sera tested had a neutralization titer of ≥ 1/400 against HIV/HCV pseudotype, and 10 of the 36 sera tested had a neutralization titer of ≥1/20 of cell culture grown HCVgenotype 1a. Neutralizing sera had increased aff
Document: Hepatitis C virus (HCV) envelope glycoproteins, E1 and E2, were used with MF59 adjuvant as a candidate vaccine for a phase I safety and immunogenicity trial. Ten of the 41 vaccinee sera tested displayed a VSV/HCV surrogate pseudotype neutralization titer of ≥1/20, 15 of the 36 sera tested had a neutralization titer of ≥ 1/400 against HIV/HCV pseudotype, and 10 of the 36 sera tested had a neutralization titer of ≥1/20 of cell culture grown HCVgenotype 1a. Neutralizing sera had increased affinity, and displayed >2 fold higher specific activity to well characterized epitopes on E1/E2, especially to the hypervariable region 1 (HVR1) of E2.
Search related documents:
Co phrase search for related documents- absence presence and longitudinal study: 1, 2, 3, 4, 5, 6
- absence presence and luciferase assay: 1
- activity level and longitudinal study: 1
- activity level and luciferase assay: 1, 2, 3
- longitudinal study and luciferase assay: 1
Co phrase search for related documents, hyperlinks ordered by date